Long-acting growth hormone has been marketed to recruit children with dwarfism for free treatment for six months Long-acting recombinant human growth hormone injection has been officially marketed in 2014 (State Drug Quantifier S20140001) under the trade name JinSaiZeng®. Phase IV clinical study of JinSaiZeng® will be conducted in our hospital, and we need to recruit several children who meet the requirements of the clinical study. The basic requirements are as follows: Wang Xinli, Department of Pediatrics, Peking University Third Hospital, Beijing, China 1. height below the 3rd percentile of the growth curve of normal children of the same age and sex; 2. height growth rate ≤ 5.0 cm/yr; 3. peak plasma GH < 10.0 ng/ml confirmed by two GH stimulation tests with different mechanisms of action; 4. bone age: girls ≤ 9 years old, boys ≤ 10 years old, bone age more than The subject is willing and able to cooperate in completing the scheduled visit, treatment plan and laboratory tests, and signing the written informed consent. If you are a child with growth hormone deficiency and are interested in this trial, please contact us. We warmly welcome all needy children with dwarfism to participate. Contact: 13581813223, 13241745944